期刊文献+

不对称二甲基精氨酸对人单核细胞株的活性及细胞周期的影响

Effect of Asymmetric Dimethylarginine on the Viability and Cell Cycle of Human Monocyte Cell Line
下载PDF
导出
摘要 目的探讨不对称二甲基精氨酸(ADMA)对单核细胞株(THP-1)的活性及细胞周期的影响.方法体外培养THP-1并且给予不同剂量的ADMA(3.75μmol/L、7.5μmol/L、15μmol/L、30μmol/L)相互作用(24h、48h、72h)后,用改良MTT法测定THP-1的活性状态及作用(24h、48h)后流式细胞仪测定细胞生长周期.实验分为空白组、阴性对照组、不同剂量ADMA组.结果在MTT测定中与阴性对照组比较发现THP-1与ADMA共同培养下能够促进细胞的生长活性,流式细胞仪在细胞周期中检测显示ADMA能提高其细胞的S期和G2/M期峰值百分比,提示细胞处于增殖状态.结论 ADMA能够促进THP-1的生长活性及增殖状态. Objective To explore the effect of ADMA on the activity and the viability and cell cycle of human monocytes.Methods THP-1 cells,human monocyte cell line,were cultured in vitro,and were incubated with different doses of ADMA(3.75 umol/L,7.5 umol/L,15umol/L,and 30umol/L) for different time(24 h,48 h,and 72 h).Then the viability of cells was evaluated by using modified MTT assay,and the cell cycle was detected by flowcytometry.According to different treatments,the cells were divided into control group,negative control group and different doses of ADMA groups.Results MTT results showed that ADMA promoted the viability of THP-1 cells,compared with the negative control group.Flow cytometry results showed that ADMA increased the peak percentage of cells in S phase and G2/Mphase,suggesting that the proliferation of cells in the state.Conclusions ADMA can promote the viability and the proliferation of monocytes,and contribute to the formation of atherosclerosis.
出处 《昆明医学院学报》 2010年第4期20-23,46,共5页 Journal of Kunming Medical College
关键词 不对称二甲基精氨酸 单核细胞株 MTT 流式细胞检测 动脉粥样硬化 细胞周期 ADMA THP-1 MTT FCM Atherosclerosis Cell cycle
  • 相关文献

参考文献6

二级参考文献18

  • 1周华,张代富,单江.福辛普利、卡托普利和缬沙坦对人血单核细胞中核因子κB的影响[J].中国动脉硬化杂志,2004,12(6):673-676. 被引量:3
  • 2萨姆布鲁克 J,分子克隆实验指南(第2版),1992年
  • 3肖作亮,胃肠激素通讯,1991年,11卷,3页
  • 4Wu C W,Cancer,1990年,65卷,1396页
  • 5章勤荣,国外医学肿瘤学分册,1988年,15卷,205页
  • 6Lin C H,Chin Med J,1984年,97卷,831页
  • 7de Lemos JA,Morrow DA,Sabatine MS,Murphy SA,Gibson CM,Antman EM,et al.Association Between plasma levels of monocyte chemoattractant protein-1 and long-term clinical outcomes in patients with acute coronary syndromes[J].Circulation,2003,107 (5):690-695.
  • 8Schmeisser A,Soehnlein O,Illmer T,Lorenz HM,Eskafi S,Roerick O,et al.ACE inhibition lowers angiotensin II-induced chemokine expression by reduction of NF-κB activity and AT1 receptor expression[J].Biochem Biophys Res Commun,2004,325 (2):532-540.
  • 9Wachtell K,Hornestam B,Lehto M,Slotwiner DJ,Gerdts E,Olsen MH,et al.Cardiovascular morbidity and mortality in hypertensive patients with a history of atrial fibrillation:The Losartan Intervention For End Point Reduction in Hypertension (LIFE) study[J].J Am Coll Cardiol,2005,45 (5):705-711.
  • 10Kowey PR,Dickson TZ,Zhang Z,Shahinfar S,Brenner BM.Losartan and end-organ protection--lessons from the RENAAL study[J].Clin Cardiol,2005,28 (3):136-142.

共引文献22

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部